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variable dependent on PTH levels. Thus, it seems statis-
tically inappropriate to apply this factor as independent
variables in the stepwise regression assay to detect “the
patients with high plasma intact PTH levels.”
Taken together, we regret to conclude that we could not
perform the stepwise analyses including active vitamin D
treatment as an independent variable in this study. We
hope your attractive hypothesis will be proved in some
other opportunities.
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Combination of intravenous
iron sucrose and ascorbic acid
in hemodialysis patients
To the Editor: We read with great interest the recent
article by Sturm et al [1] demonstrating ascorbic acid
together with iron sucrose can increase the intracellu-
lar labile iron pool and iron mobilization to transferrin
in human hepatoma HepG2 cells. The authors reported
that neither ferric gluconate nor iron dextran has such
an effect. The extrapolation of this important finding to
clinical practice, as it was noted in the manuscript, led to
the conclusion that iron sucrose could be a more benefi-
cial iron preparation for further response to recombinant
human erythropoietin (rHuEPO) with adjuvant ascorbic
acid replacement. As it was cited in the paper, the studies
investigating the role of ascorbic acid as an adjuvant ther-
apy to rHuEPO enrolled the hemodialysis patients with
iron overload. Most of the studies on this issue excluded
the patients on iron replacement due to iron overload [2,
3] and reported a beneficial effect of ascorbic acid only
in patients with functional iron deficiency. The effect of
concomitant use of ascorbic acid with intravenous iron on
rHuEPO response has not been extensively evaluated.
However, in our recent randomized crossover study, we
investigated this issue in all hemodialysis patients, includ-
ing patients with normal iron status, as well. All patients
were on maintenance intravenous iron sucrose and were
administrated 500 mg ascorbic acid 3 times a week for 6
months. We found that supplementation of ascorbic acid
resulted in a significant increase in hemoglobin levels to-
gether with a significant increase in transferrin saturation
in approximately 65% of the patients [4]. Therefore, iron
sucrose and ascorbic acid can be a better combination
due to increasing the amount of bioavailable iron from
iron sucrose. However, we recommend further clinical
studies to evaluate the effect of other intravenous iron
preparations in combination with ascorbic acid.
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Continuous renal replacement
therapy in the critically ill
patient
To the Editor: I read with interest the discussion of
Dr. Mehta [1]. As “positive” findings, I see the follow-
ing: (1) The treatment protocol is adapted to the widely
available Prisma machine. Nevertheless, in the future I
hope to see more versatile models permitting the use of
other than Hospal filters, Hospal “sets,” and more flexible
pump functions; (2) the recipe for citrate local anticoagu-
lation, which reduces side effects in patients und prolongs
filter function; (3) the great idea of partial predilution
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mode contributes, but does not resolve, problems of high
volume hemodiafiltration. The focus on high blood flow
should not be lost; and (4) the application of the “alter-
nate” mode of prescription of CRRT, which hopefully
will facilitate the cooperation with the intensivists.
The major concern is treatment dose. When accepting
the data of Ronco [2], this patient is undertreated: total
small molecular clearance, 37 mL/min versus 48 mL/min.
Contribution of convective clearance, 25 mL/min versus
48 mL/min.
Are there any hints indicating that smaller treatment
doses than those of Ronco might be adequate?
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Herb-associated
carcinogenicity and chronic
renal failure in Asian patients
with kidney cancer and
hypertension
To the Editor: With great interest, we have read the
paper in a recent issue of Kidney International by Choi
et al [1] that hypertension is an independent risk factor of
kidney cancer mortality. However, we wonder whether
all the reported deaths of “kidney cancer” were defi-
nitely pathology-proven renal cell carcinomas (RCCs) or
if some of them were cancers of the renal pelvis [i.e., tran-
sitional cell carcinomas (TCCs)] in nature. Though RCCs
account for about 80% to 85% of all primary renal neo-
plasms, TCCs arising from the renal pelvis are the next
most common and account for 7%∼8% of primary renal
neoplasms [2]. Further, considering the high frequency of
using herbs as alternative medicine for chronic diseases
(e.g., hypertension, heart disease, diabetes, asthma, etc.)
in Asian aged people, the risk of herb-associated carcino-
genicity (e.g., aristolochic acid-associated uroepithelial
cancers in human [3], TCCs, and RCCs in rats) should be
further investigated. Meanwhile, the patients’ renal func-
tion should also be analyzed because chronic renal failure
(e.g., tuberous sclerosis, autosomal-dominant polycystic
kidney disease, and von Hippel-Lindau disease) or end-
stage renal disease (e.g., RCCs develop in 3.8% to 4.2%
of ESRD patients with acquired polycystic kidney dis-
ease), per se, is somewhat associated with RCCs [4], and
it may be the result of herb nephropathy in patients with
significant history of herb use. Ideally, the renal function
and pathology of these 92 deaths from “kidney cancer”
should be reviewed to exclude the aforementioned con-
founding factors and search the possible evidence of herb
nephropathy correlated to TCCs or RCCs.
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Dehydration versus volume
depletion
To the Editor: In his recent Nephrology Forum, Dr.
Friedman [1] makes a number of interesting and cogent
observations regarding enteral and parenteral fluid and
electrolyte therapy in infants and children. However, I
believe discussions of fluid and electrolyte disorders, and
their treatments, become much clearer and more easily
understood when terms such as “hydration,” “dehydra-
tion,” “volume depletion,” and “volume expansion” are
used in a more exacting and restricted fashion. As Menge
et al [2] describe in their article, “hydration” is best used
to define the ratio between total body solute and total
